Venous thromboembolism in hospitalized patients with active cancer

Clinical and Applied Thrombosis/Hemostasis

Volumn 19, Issue 5, 2013, Pages 469-475

  Piazza, Gregory ^a   Rao, Amanda F ^a   Nguyen, Thanh Nha ^a   Seger, Andrew C ^b   Hohlfelder, Benjamin ^a   Fanikos, John ^a   Goldhaber, Samuel Z ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

cancer; deep vein thrombosis; prophylaxis; pulmonary embolism; treatment; venous thromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; ANTINEOPLASTIC AGENT; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ADRENAL CANCER; ADULT; AGED; ARTICLE; BILE DUCT CANCER; BLADDER CANCER; BRAIN CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CAUSE OF DEATH; CERVICAL CANCER ELECTRO OPTICAL SENSOR; COLORECTAL CANCER; DISEASE COURSE; ESOPHAGUS CANCER; FEMALE; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; INTESTINE CANCER; KIDNEY CANCER; LEUKEMIA; LUNG CANCER; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MELANOMA; MESOTHELIOMA; MYELODYSPLASTIC SYNDROME; MYELOMA; NEOPLASM; OUTCOME ASSESSMENT; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROPHYLAXIS; PROSTATE CANCER; STOMACH CANCER; TESTIS CANCER; UTERINE TUBE CARCINOMA; UTERUS CANCER; VENOUS THROMBOEMBOLISM;

CANCER; DEEP VEIN THROMBOSIS; PROPHYLAXIS; PULMONARY EMBOLISM; TREATMENT; VENOUS THROMBOEMBOLISM;

AGED; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PULMONARY EMBOLISM; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 84879116406     PISSN: 10760296     EISSN: 19382723     Source Type: Journal    
DOI: 10.1177/1076029613481844     Document Type: Article

References (32)

1. Agnelli G, Verso M. Management of venous thromboembolism in patients with cancer. J Thromb Haemost. 2011 ; 9 (suppl 1). 316-324
2. Cronin-Fenton DP, Sondergaard F, Pedersen LA, et al. Hospitalisation for venous thromboembolism in cancer patients and the general population: a population-based cohort study in Denmark, 1997-2006. Br J Cancer. 2010 ; 103 (7). 947-953
3. Seddighzadeh A, Shetty R, Goldhaber SZ. Venous thromboembolism in patients with active cancer. Thromb Haemost. 2007 ; 98 (3). 656-661
4. Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000 ; 343 (25). 1846-1850
5. Stein PD, Beemath A, Meyers FA, Skaf E, Sanchez J, Olson RE. Incidence of venous thromboembolism in patients hospitalized with cancer. Am J Med. 2006 ; 119 (1). 60-68
6. Yu YB, Gau JP, Liu CY, et al. A nation-wide analysis of venous thromboembolism in 497,180 cancer patients with the development and validation of a risk-stratification scoring system. Thromb Haemost. 2012 ; 108 (2). 225-235
7. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer. 2007 ; 110 (10). 2339-2346
8. Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008 ; 111 (10). 4902-4907
9. Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002 ; 100 (10). 3484-3488
10. Trujillo-Santos J, Nieto JA, Tiberio G, et al. Predicting recurrences or major bleeding in cancer patients with venous thromboembolism. Findings from the RIETE registry. Thromb Haemost.. 2008 ; 100 (3). 435-439
11. Trujillo-Santos J, Casas JM, Casado I, et al. Thirty-day mortality rate in women with cancer and venous thromboembolism. Findings from the RIETE Registry. Thromb Res.. 2011 ; 127 (suppl 3). S1 - S4
12. Kucher N, Koo S, Quiroz R, et al. Electronic alerts to prevent venous thromboembolism among hospitalized patients. N Engl J Med. 2005 ; 352 (10). 969-977
13. Piazza G, Rosenbaum EJ, Pendergast W, et al. Physician alerts to prevent symptomatic venous thromboembolism in hospitalized patients. Circulation. 2009 ; 119 (16). 2196-2201
14. The GUSTO investigators. N Engl J Med. 1993 ; 329 (10). 673-682
15. CohenA.Rivaroxaban compared with enoxaparin for prevention of venous thromboembolism in acutely ill medical patients; 2011. http://myamericanheart. org/idc/groups/ahamah-public/@wcm/@sop/@scon/documents/downloadable/ucm-425442. pdf. Accessed 10/25/11.
16. Goldhaber SZ, Leizorovicz A, Kakkar AK, et al. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med. 2011 ; 365 (23). 2167-2177
17. Hull RD, Schellong SM, Tapson VF, et al. Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial. Ann Intern Med. 2010 ; 153 (1). 8-18
18. Agnelli G, George DJ, Kakkar AK, et al. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med. 2012 ; 366 (7). 601-609
19. Agnelli G, Gussoni G, Bianchini C, et al. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol. 2009 ; 10 (10). 943-949
20. Di Nisio M, Porreca E, Ferrante N, Otten HM, Cuccurullo F, Rutjes AW. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Cochrane Database Syst Rev. 2012 ; 2 :
21. Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2012 ; 141 (suppl 2). e195S - e226S
22. Qaseem A, Chou R, Humphrey LL, Starkey M, Shekelle P. Venous thromboembolism prophylaxis in hospitalized patients: a clinical practice guideline from the American college of physicians. Ann Intern Med. 2011 ; 155 (9). 625-632
23. Streiff MB, Bockenstedt PL, Cataland SR, et al. Venous thromboembolic disease. J Natl Compr Canc Netw. 2011 ; 9 (7). 714-777
24. Fanikos J, Rao A, Seger AC, et al. Venous thromboembolism prophylaxis for medical service-mostly cancer-patients at hospital discharge. Am J Med. 2011 ; 124 (12). 1143-1150
25. Akl EA, Labedi N, Barba M, et al. Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev. 2011 ; ( 6 ):
26. Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2012 ; 141 (suppl 2). e419S - e494S
27. Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003 ; 349 (2). 146-153
28. van Doormaal FF, Di Nisio M, Otten HM, Richel DJ, Prins M, Buller HR. Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer. J Clin Oncol. 2011 ; 29 (15). 2071-2076
29. Kahn SR, Shrier I, Julian JA, et al. Determinants and time course of the postthrombotic syndrome after acute deep venous thrombosis. Ann Intern Med. 2008 ; 149 (10). 698-707
30. Piazza G, Goldhaber SZ. Chronic thromboembolic pulmonary hypertension. N Engl J Med. 2011 ; 364 (4). 351-360
31. MacDougall DA, Feliu AL, Boccuzzi SJ, Lin J. Economic burden of deep-vein thrombosis, pulmonary embolism, and post-thrombotic syndrome. Am J Health Syst Pharm. 2006 ; 63 (20 suppl 6). S5 - S15
32. Alpert JS. Are data from clinical registries of any value?. Eur Heart J. 2000 ; 21 (17). 1399-1401